Welcome to our dedicated page for Cardlytics SEC filings (Ticker: CDLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Cardlytics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Cardlytics's regulatory disclosures and financial reporting.
Cardlytics, Inc. director and Chief Executive Officer Amit Gupta reported an open-market sale of 69,833 shares of common stock at a weighted average price of $1.187 per share. According to the filing, the shares were sold solely to satisfy tax withholding obligations from RSUs that vested on April 1, 2026, and were not sold for any other purpose. Following this tax-related sale, Gupta continues to hold 987,387 shares of Cardlytics common stock directly.
CDLX affiliate reported proposed sales of common stock under Form 144. The filing lists 69,833 shares tied to a restricted stock vesting event on 04/02/2026 described as compensation. The excerpt also shows recent sales by Amit Gupta, including 52,049 shares on 02/17/2026 and 62,549 shares on 04/01/2026.
Cardlytics, Inc. Chief Executive Officer Amit Gupta reported RSU vesting and related share sales. On April 1, 2026, he acquired 514,350 shares of common stock at a conversion price of $0.00 per share through the exercise of restricted stock units. The same day and on April 2, 2026, he sold a total of 116,774 common shares at weighted average prices of $0.99 and $1.042 per share. Footnotes state these sales were made solely to satisfy tax withholding obligations from RSUs that vested on April 1, 2026 and were not for any other purpose. After these transactions, he directly held 1,057,220 shares of Cardlytics common stock.
Cardlytics, Inc. Chief Legal & Privacy Officer Lynton Nicholas Hollmeyer exercised restricted stock units into 85,290 shares of common stock on April 1, 2026. He then sold 40,296 shares at a weighted average price of $0.99 solely to cover tax withholding obligations, and now directly holds 167,856 shares.
CDLX reported a Form 144 notice to sell 54,225 shares of Common Stock. The filing lists these shares as "Restricted Stock Vesting" issued on 04/01/2026 in connection with Compensation. The excerpt also lists multiple sales by Amit Gupta during the past three months, showing individual sale dates and share counts.
CDLX Form 144 lists a proposed resale of 40,296 shares of Common Stock tied to Restricted Stock Vesting dated 03/31/2026. The filing also shows a prior sale of 6,253 shares by Nicholas H. Lynton on 01/05/2026 and references 55,054,268 in a column dated 04/01/2026.
CDLX notified a Rule 144 notice for proposed resale of 62,549 shares of Common Stock. The filing lists the securities as resulting from Restricted Stock Vesting dated 03/31/2026 and classifies the transaction as compensation. The excerpt also reports prior dispositions by Amit Gupta totaling 102,015 shares across three trades in January–February 2026 with dollar proceeds shown per trade.
Cardlytics, Inc. is soliciting proxies for its Annual Meeting on May 20, 2026 to elect three Class II directors, ratify Deloitte & Touche LLP as auditors, seek stockholder approval for a board‑determined reverse stock split at a ratio of 1:5 to 1:15 (with corresponding authorized shares reduction), and hold an advisory vote on named executive officer compensation. The record date is March 25, 2026 and there were 55,070,709 shares outstanding on that date. Proxy materials and voting instructions will be furnished primarily via the Internet.
CDLX — Notice of proposed resale of 50,000 shares of Common Stock. The filing lists 50,000 common shares tied to a Restricted Stock Vesting event dated 08/14/2024 with the issuer shown as the source and the transaction labeled Compensation.
The form records a recent sale of 8,607 shares on 01/05/2026 for $10,072.77. The filing identifies a brokerage account at Fidelity Brokerage Services and shows a filing date of 03/25/2026 on NASDAQ-listed securities.
Cardlytics, Inc. has completed the sale of its Bridg platform business to PAR Technology Corporation, transferring assets and rights primarily related to Bridg to PAR’s subsidiary DB Sub, LLC. As consideration, Cardlytics received 1,810,222 shares of PAR common stock, reflected as $25.4 million of stock in the pro forma adjustments.
Bridg is now treated as a discontinued operation, and Cardlytics has filed unaudited pro forma condensed consolidated financial statements for 2023–2025. On a pro forma basis for 2025, revenue from continuing operations is $212.3 million versus historical $233.3 million, and the net loss from continuing operations narrows to $91.5 million from $103.5 million. For 2024, the pro forma net loss from continuing operations is $40.4 million, compared with a historical net loss of $189.3 million, largely due to removing Bridg-related impairment charges.
The company estimates a $13.9 million gain on the transaction, based on the stock consideration, expected transaction costs of about $1.6 million, and Bridg net assets of approximately $9.9 million as of December 31, 2025. Management emphasizes that these pro forma figures and the gain estimate are preliminary and provided for illustrative purposes only.